A small, randomized trial of 2 doses of intranasal insulin showed improvements in memory and functioning and improved CSF biomarker profiles among patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) with treatment over placebo.
The SNIFF-120 trial was a 4-month, randomized, double-blind trial of placebo vs 2 doses of intranasal insulin: 20 or 40 IU daily. One hundred four patients with AD or amnestic MCI participated; patients with diabetes were excluded.
Intranasal Insulin Shows Benefit in Mild Cognitive Impairment and Alzheimer's Disease
Комментариев нет:
Отправить комментарий